Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLPG
Previous Symbol
CUSIPN/A
Phone321-534-2900
Debt
Debt-to-Equity RatioN/A
Current Ratio5.17
Quick Ratio5.17
Price-To-Earnings
Trailing P/E Ratio-38.75
Forward P/E Ratio-59.48
P/E GrowthN/A
Sales & Book Value
Annual Sales$176.13 million
Price / Sales29.76
Cash FlowN/A
Price / Cash FlowN/A
Book Value$22.46 per share
Price / Book4.56
Profitability
EPS (Most Recent Fiscal Year)($2.64)
Net Income$-130,780,000.00
Net Margins-30.65%
Return on Equity-7.66%
Return on Assets-5.85%
Miscellaneous
Employees600
Outstanding Shares51,240,000
Market Cap$5.13 billion
OptionableOptionable
GALAPAGOS NV/S (NASDAQ:GLPG) Frequently Asked Questions
What is GALAPAGOS NV/S's stock symbol?
GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG."
How were GALAPAGOS NV/S's earnings last quarter?
GALAPAGOS NV/S (NASDAQ:GLPG) released its quarterly earnings data on Friday, October, 26th. The biotechnology company reported $0.33 EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.70. The biotechnology company earned $119.99 million during the quarter, compared to the consensus estimate of $82.15 million. GALAPAGOS NV/S had a negative return on equity of 7.66% and a negative net margin of 30.65%. View GALAPAGOS NV/S's Earnings History.
When is GALAPAGOS NV/S's next earnings date?
What price target have analysts set for GLPG?
10 brokers have issued twelve-month price targets for GALAPAGOS NV/S's stock. Their forecasts range from $90.00 to $157.00. On average, they expect GALAPAGOS NV/S's stock price to reach $122.6250 in the next twelve months. This suggests a possible upside of 19.9% from the stock's current price. View Analyst Price Targets for GALAPAGOS NV/S.
What is the consensus analysts' recommendation for GALAPAGOS NV/S?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 3 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GALAPAGOS NV/S.
What are Wall Street analysts saying about GALAPAGOS NV/S stock?
Here are some recent quotes from research analysts about GALAPAGOS NV/S stock:
- 1. According to Zacks Investment Research, "Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. " (11/13/2018)
- 2. BTIG Research analysts commented, "Before-mkt-open on Thursday, Galapagos hosted their 1Q18 financials call and provided an update on clinical programs for 2018. We expect a ramp in clinical efforts for the Cystic Fibrosis portfolio heading into 2H2018, although we agree with the general consensus that the CF effort remains a ‘show-me; story. Beyond CF, we are encouraged by the commitment to the Phase 3 Isabela studies for GLPG1690 in the treatment of Idiopathic Pulmonary Fibrosis (IPF), and remain positive on upcoming data on filgotinib. We reiterate our Buy rating and $118 PT." (4/29/2018)
Has GALAPAGOS NV/S been receiving favorable news coverage?
Media coverage about GLPG stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GALAPAGOS NV/S earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of GALAPAGOS NV/S's key competitors?
Some companies that are related to GALAPAGOS NV/S include Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Beigene (BGNE), Perrigo (PRGO), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS).
Who are GALAPAGOS NV/S's key executives?
GALAPAGOS NV/S's management team includes the folowing people:
- Mr. Onno van de Stolpe, Co-Founder, MD, CEO & Exec. Director (Age 59)
- Mr. Bart Filius MBA, CFO & COO (Age 48)
- Dr. Piet Wigerinck, Chief Scientific Officer (Age 54)
- Ms. Elizabeth Goodwin, VP of Investor Relations & Corp. Communications
- Ms. Veronique Deiteren, Head of HR
When did GALAPAGOS NV/S IPO?
(GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.
Who are GALAPAGOS NV/S's major shareholders?
GALAPAGOS NV/S's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (1.43%), BlackRock Inc. (0.71%), Baker BROS. Advisors LP (0.46%), Credit Suisse AG (0.37%), Jane Street Group LLC (0.36%) and Laurion Capital Management LP (0.34%).
Which institutional investors are selling GALAPAGOS NV/S stock?
GLPG stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Aquilo Capital Management LLC, Dorsey Wright & Associates, Alliancebernstein L.P., Baker BROS. Advisors LP, Peregrine Capital Management LLC and Macquarie Group Ltd..
Which institutional investors are buying GALAPAGOS NV/S stock?
GLPG stock was bought by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Marshall Wace LLP, Jane Street Group LLC, Credit Suisse AG, Monashee Investment Management LLC, BlackRock Inc., Janus Henderson Group PLC and Henry James International Management Inc..
How do I buy shares of GALAPAGOS NV/S?
Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GALAPAGOS NV/S's stock price today?
One share of GLPG stock can currently be purchased for approximately $102.31.
How big of a company is GALAPAGOS NV/S?
GALAPAGOS NV/S has a market capitalization of $5.13 billion and generates $176.13 million in revenue each year. The biotechnology company earns $-130,780,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. GALAPAGOS NV/S employs 600 workers across the globe.
What is GALAPAGOS NV/S's official website?
How can I contact GALAPAGOS NV/S?
GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]
MarketBeat Community Rating for GALAPAGOS NV/S (NASDAQ GLPG)
MarketBeat's community ratings are surveys of what our community members think about GALAPAGOS NV/S and other stocks. Vote "Outperform" if you believe GLPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
